SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACMI - Accumed Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sigmund who wrote (1214)1/19/1998 2:11:00 PM
From: Frank Buck  Read Replies (1) of 1894
 
Sigmund,

The more elaborate detailing and further clarification of the newly announced venture will most likely be at the center-stage of the talks tomorrow.

A benign evaluation of the venture, or even a great endearment to it by the analysts' may not have an immediate impact on ACMI shareprice. A reiteration of a "strong-buy" by current analysts without a commensurate increase in their own institutional account holdings will be like yelling "come", for a second time, to a deaf dog. I say this because their original strong-buys had never been publicly removed, yet they were systematically reducing their own exposure for the past several months.

I do believe that your statement; .....they (AccuMed) probably wouldn't do it if they thought it would be disadvantageous to shareholders. is correct. My feel is that the analyst will also consider the "equity-carving" to be a determining factor in an earlier than expected break-even.

However I am unsure if the resultant renewal of jubuliant outcries will have an immediate positive impact on the shareprice. I still believe that given the past faux pas of the analysts' and the Company (regarding EPS dissapointments) that a firm strong quarter or two will be the motivating stimulus in the stock movement. Or as previously mentioned, an actual physical event such as a "nominal"
token buy-back or an immediate large-scale order for cytopathology equipment. As previously mentioned a considerable re-purchase of ACMI stock by the analyst/market makers will also work.

Frank

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News